Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area

The commercial release of the New Oral Anticoagulants (NOACs) has been the most significant change in anticoagulant therapy in recent years. The work aimed to evaluate the economic and health impact for the Local Health Agency Barletta-Andria-Trani (BT). Through the Regional Information System data about naïve patients on NOAC treatment and patients on anti-vitamin-k (VKA), treatments were extrapolated. We assessed therapeutic continuity, pharmaceutical expenditure, hospitalizations, and deaths in 2017 and 2018. Therapeutic continuity was similar in the two groups. The number and the average cost of hospitalizations for a patient treated with VKAs were almost constant, while those of patients treated with NOACs decreased. The treatment of adult-aged naïve patients with NOACs, compared to VKAs therapy, involves an increase in expenditure of about 100€ for a patient, but the reduced hospitalizations could generate, in the long term, saving for the Health System. Clinical data, according to the Real-World Data, confirmed the safety and effectiveness of these drugs. However, attention to the special population is necessary to improve the safety and effectiveness of NOACs. Innovative formulations for pediatric patients are being developed. The challenge for Health Systems is the appropriate use of available resources through health interventions with transversal competences

Verso nuovi modelli di cura per il paziente con asma grave: dieci proposte per lo scenario post DM77

Dal 2023 si è aperta la stagione in cui Regioni e ASL devono riempire di contenuti e modelli di servizio le nuove o rinnovate strutture dell’assistenza sanitaria territoriale delineate dalla Missione 6 del PNRR e dal DM 77/22. In quest’epoca di cambiamento e innovazione, non è solo il management a dover definire le priorità strategiche ma anche le comunità di professionisti sono chiamate a interrogarsi su come queste nuove configurazioni possono rispondere ai bisogni dei propri pazienti. Il presente paper mette in luce la prospettiva dei professionisti che si occupano di pazienti con asma grave tramite lo sviluppo di dieci proposte che riguardano logiche di stratificazione della popolazione, nuovi modelli e servizi dell’assistenza territoriale, telemedicina e multicanalità

Characteristics and Drug Utilization of Patients with Hereditary Angioedema in Italy, a Real-World Analysis

This real-world analysis investigated the characteristics and treatment patterns of patients with hereditary angioedema (HAE) in Italy using the administrative data of health units across Italy. Patients were identified via exemption code or HAE-specific treatments (thus, all known forms, type I, II and, III, were included). The index date was that of first prescription of HAE treatments within the inclusion period (01/2010–06/2021) or of the date of exemption. The number of HAE patients included was 148 (43.2% male, mean age 43.3 years). Gastrointestinal disorders affected 36.5% patients, hypertension affected 28.4%, hypercholesterolemia affected 11.5%, and depression affected 9.5%. The frequent gastrointestinal involvement was further confirmed by the use of antiemetics and systemic antihistamines that doubled after the index date. Among patients enrolled by treatment (n = 125), n = 105 (84%) were receiving a treatment for acute attacks. This analysis provided insights into the characterization of patients with HAE and their management in Italian clinical practice, suggesting that an unmet therapeutic need could be present for such patients in terms of the clinical burden